Healius Ltd FY26 Results Presentation
Key points
- Group revenue growth of 2.1% to $1,373.2m
- Pathology revenue growth of 1.8% to $1,329.6m
- Underlying EBIT up 76.6% to $30.2m
- Net debt reduced to $32.8m
- Exploring sale of Agilex Biolabs
Full summary
Healius Ltd announced its FY26 results, reporting a 2.1% increase in underlying revenue to $1,373.2 million. Pathology revenue grew by 1.8% to $1,329.6 million, driven by improved revenue mix and strong growth in genomics and clinical trials. Underlying EBIT increased by 76.6% to $30.2 million, reflecting strong cost control and margin expansion. Agilex Biolabs revenue grew 14.1% to $43.6 million, with EBIT more than doubling to $6.4 million. The company is exploring a sale of Agilex Biolabs in response to strong interest from potential acquirers. Healius ended FY26 with net debt of $32.8 million, well within its banking covenants.
Guidance
FY27 EBIT expected to be in line with consensus of $39.7m
Outlook
Healius expects FY27 EBIT to be in line with consensus of $39.7m, with continued growth in pathology and strong performance from Agilex Biolabs.
Summary generated by a large language model. Please interpret with care.